Cyclosporin A (Ciclosporin, Cyclorin, Neoral, Ramihyphin A, Sandimmun, Sandimmune, OL 27-400, S 7481F1, CyA, Antibiotic S 7481F1)

Cyclosporin A is a noncytotoxic, natural, 11 amino acid cyclic peptide used clinically as an immunosuppressant for the treatment of autoimmune and inflammatory disorders and to prevent organ rejection after transplantation. Cyclosporin acts chiefly by inhibiting T lymphocyte function, which is vital for the propagation of inflammation. Cyclosporin A does not suppress the activity of other hematopoietic cells, does not cause bone marrow suppression and has a rapid onset of action as opposed to other immunosuppressive agents. Nevertheless, Cyclosporin A -induced nephrotoxicity remains an important clinical problem, and oxidative stress has been implicated as a potential responsible mechanism.\n\nCyclosporine is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the fungus species Beauveria nlyea. Chemically, cyclosporine is designated as [R-[R*,R*-(E)]]-cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha -amino-butyryl- N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).\n\nStorage and Stability\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C8900-04

Size

1g

Form

Supplied as a lyophilized powder without additives. Reconstitute sterile deionized H2O to a concentration (same/more than)0.1mg/ml, which can then be further diluted to other aqueous solution.

Purity

(same/more than) 98% as determined by RP-HPLC and MALDI-TOF

References

1. Pathophysiological response of rhesus monkey kidney epithelial cells exposed to cyclosporine A. Biomed Sci Instrum 2006;42:84-9. 2. Cyclosporine a and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study j. Sairanen, T. L. J. Tammela, m. Leppilahti, m. Multanen, I. Paananen, k. Lehtoranta and m. Ruutu j urol, 174: 2235-2238, 2005. J Urol 2006 Aug;176(2):838. 3. Effects of cyclosporine A in hyperzincaemia and hypercalprotectinaemia. Acta Paediatr 2006 Jul;95(7):857-60. 4. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid. Int J Pharm 2006 May 16;5. Beyond Cyclosporine: A Systematic Review of Limited Sampling Strategies for Other Immunosuppressants. Ther Drug Monit 2006 Jun;28(3):419-430. 6. Renal biopsy findings in children receiving long-term treatment with cyclosporine a given as a single daily dose. Tohoku J Exp Med 2006 Jul;209(3):191-6.